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Multi-component assessment of chronic obstructive
pulmonary disease: an evaluation of the ADO and DOSE
indices and the global obstructive lung disease categories
in international primary care data sets
Rupert C Jones1, David Price2, Niels H Chavannes3, Amanda J Lee4, Michael E Hyland5, Björn Ställberg6, Karin Lisspers6, Josefin Sundh7,
Thys van der Molen8 and Ioanna Tsiligianni8 On behalf of the UNLOCK Group of the IPCRG
Suitable tools for assessing the severity of chronic obstructive pulmonary disease (COPD) include multi-component indices and the
global initiative for chronic obstructive lung disease (GOLD) categories. The aim of this study was to evaluate the dyspnoea,
obstruction, smoking, exacerbation (DOSE) and the age, dyspnoea, obstruction (ADO) indices and GOLD categories as measures of
current health status and future outcomes in COPD patients. This was an observational cohort study comprising 5,114 primary care
COPD patients across three databases from UK, Sweden and Holland. The associations of DOSE and ADO indices with (i) health
status using the Clinical COPD Questionnaire (CCQ) and St George’s Respiratory Questionnaire (SGRQ) and COPD Assessment test
(CAT) and with (ii) current and future exacerbations, admissions and mortality were assessed in GOLD categories and DOSE and
ADO indices. DOSE and ADO indices were significant predictors of future exacerbations: incident rate ratio was 1.52 (95%
confidence intervals 1.46–1.57) for DOSE, 1.16 (1.12–1.20) for ADO index and 1.50 (1.33–1.68) and 1.23 (1.10–1.39), respectively, for
hospitalisations. Negative binomial regression showed that the DOSE index was a better predictor of future admissions than were
its component items. The hazard ratios for mortality were generally higher for ADO index groups than for DOSE index groups. The
GOLD categories produced widely differing assessments for future exacerbation risk or for hospitalisation depending on the
methods used to calculate them. None of the assessment systems were excellent at predicting future risk in COPD; the DOSE index
appears better than the ADO index for predicting many outcomes, but not mortality. The GOLD categories predict future risk
inconsistently. The DOSE index and the GOLD categories using exacerbation frequency may be used to identify those at high risk
for exacerbations and admissions.
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INTRODUCTION
COPD is a growing burden on patients and healthcare systems,
with a minority of patients being responsible for the majority of
healthcare costs.1 The Global Initiative for Chronic Obstructive
Lung Disease (GOLD) recommends that measurement of COPD
severity should move from lung function alone to assessing
current symptoms and future risk for exacerbations.2 Although
current symptoms may be assessed using validated measures,
identifying those at increased risk of exacerbations and admis-
sions is more difficult. However, once identified, proven measures
to minimise such risks may be applied to reduce the burden of
exacerbations. These measures include optimal drug therapy,
education for self-management and behavioural change such as
smoking cessation, exercise and nutrition.2
A range of indices are available for use in routine clinical
settings and none seem to be perfect for assessing prognosis.3
The value of a COPD severity index would be greatest if it (i) used
items that are easy to collect, (ii) used items that are valid in their
own right, (iii) provided better associations with patient-centred
outcomes and healthcare consumption than with individual
components and (iv) identified patients at increased risk for
future events including exacerbations, hospital admissions and
mortality.4
The GOLD strategy referred to three multi-component indices
that assess COPD severity, the BODE, DOSE and ADO indices, but
preferred a new system of GOLD categories based on current
symptoms and future risk.2,5 The three multi-component indices
were statistically derived and validated, whereas the GOLD
categories were designed by an expert committee without
statistical derivation. Subsequent studies have found that the
GOLD categories do not accurately predict future risk.6–8
The BODE and ADO indices were derived as prognostic markers,
but they also predict other patient-related outcomes including
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health status and functional capacity.9,10 However, the BODE index
requires the 6-min walking test (6MWT), which limits its clinical
use. The DOSE index was derived as a predictor of health status,11
but also reflects mortality,11,12 future exacerbations13 and decline
in health status.14 The items used in these assessment systems are
shown in Table 1.
The GOLD strategy produces four categories, based on current
symptoms and future risk, which may be used to guide treatment.
Several alternative methods are described to calculate the
categories: future risk may either be estimated by the forced
expiratory volume in one second as a percentage of predicted
(FEV1%) or exacerbation frequency. Symptoms may be estimated
using either the MRC dyspnoea scale, the COPD Assessment Test
(CAT) or the Clinical COPD Questionnaire (CCQ).
In this study, we aimed to assess the value of the new GOLD
categories and contrast them with existing multi-component
indices suitable for use in primary care.
RESULTS
Health status
The PRAXIS study consisted of 562 patients with 27% in GOLD
airflow obstruction stage I, 41% in stage II, 25% in stage III and 7%
in stage IV. The mean age was 63.6 years (standard deviation (s.d.)
7.7). During the average study follow-up period of five years, 116
patients (21%) died. The DOSE index ranged from 0 to 7 and 18%
had an index of44. The ADO index ranged from 0 to 8 and 39%
had an index44. In the Bocholtz data set the DOSE index ranged
from 0 to 6 and 9% had an index44. The ADO index ranged from
0 to 10 and 37% had an index44. The Bocholtz and PRAXIS study
data sets both showed that the DOSE index was more strongly
correlated to various health status measures than the ADO index
in cross-sectional data (Table 2).
Healthcare consumption
In the Optimum Patient Care (OPCRD) data set of 4,400 patients,
the DOSE index ranged from 0 (mild) to 8 (severe); 24.5%
(n= 1,077) of subjects had a score of 4 or more. The ADO index
ranged from 0 to 10 and 56.7% had an index44. The prevalence
of GOLD categories is shown in Figure 1. Although neither the
DOSE nor the ADO index was a strong predictor of future events,
the DOSE index performed better than its component items or the
ADO index. The DOSE index was more highly correlated with
number of exacerbations in the subsequent 12 months (r= 0.32)
compared with the ADO index (r= 0.11, both Po0.001) to FEV1%
(r=− 0.06) and the MRC dyspnoea scale r= 0.03). For a unit
increase in DOSE or ADO index, the unadjusted odds ratio
(95% confidence interval (CI)) for future exacerbation was 1.60
(1.52–1.67) and 1.14 (1.10–1.19), respectively. Similar figures for
odds of future hospitalisation were DOSE 1.45 (1.27–1.65) and
ADO 1.22 (1.07–1.39).
Table 3 shows the negative binomial regression models
predicting the number of exacerbations and hospitalisations for
DOSE and ADO indices and a range of healthcare measures.
Compared with models for the ADO index and those for
healthcare measures such as FEV1%, smoking status, age or MRC
scale, the model with DOSE as a predictor showed a better overall fit
(as assessed by the lowest AIC). A similar picture was seen using
number of exacerbations as the outcome. The unadjusted incident
rate ratio for hospital admission in the subsequent year for patients
with a DOSE index 44 was 2.97 (95% CI 2.03–4.36) and that for
having an exacerbation in the next year was 2.99 (95% CI 2.66–3.37).
For the 7,105 OPCRD patients having both valid DOSE and ADO
indices, receiver operator characteristic again showed that the
DOSE index was a weak, but better predictor than the ADO index
for future events. For hospitalisations, the areas under the curve
for DOSE index was 0.64 (95% CI 0.57–0.71) and that for the ADO
index was 0.57 (95% CI 0.50–0.64); for exacerbations, the areas
under the curve for DOSE index was 0.58 (95% CI 0.55–0.60) and
that for the ADO index was 0.53 (95% CI 0.50–0.55).
Mortality
Both DOSE and ADO index groups (score 4–5 or 45) were
significantly associated with mortality (Table 4). Adjustment for
gender and co-morbid cardiovascular disease did not substantially
change the hazard ratios.
GOLD categories
Of the 3,015 patients in the OPCRD data set who had valid data on
all the required items, the mean (s.d.) age was 72.6 (9.3) years.
There were 342 (11.3%) non-smokers, 1,961 (65%) ex-smokers, 648
(21.5%) current smokers and 64 (2.1%) with missing smoking data.
We compared the proportion of OPCRD patients across
categories A to D when using alternative methods allowed in
the GOLD strategy (Figure 1). The proportions varied greatly
according to whether the MRC dyspnoea scale or CAT score was
Table 1. The items used in the GOLD, BODE, DOSE and ADO multi-component assessment systems
Measure Body mass index FEV1% predicted grade MRC dyspnoea scale 6-min walk test Age Smoking status Exacerbation frequency Health status
CAT or CCQ
BODE √ √ √ √
ADO √ √ √
DOSE √ √ √ √
GOLD √ or * √ or ** √ or * √ or **
Abbreviations: ADO, age, dyspnoea, obstruction; CCQ, clinical COPD questionnaire; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease;
DOSE, dyspnoea, obstruction, smoking, exacerbation; GOLD, global initiative for chronic obstructive lung disease.
√ or * signifies either FEV1% (forced expiratory volume in one second as a percentage of predicted) or exacerbation frequency.
√ or ** signifies either MRC dyspnoea scale or health status measure (CCQ or CAT).
Table 2. Rank correlations between health status measures and the
DOSE and ADO indices
Study DOSE index P value ADO index P value
Bocholtz cohort N= 154
CCQ score − 0.55 o0.001 − 0.41 o0.001
SGRQ symptoms − 0.36 o0.001 − 0.26 0.001
SGRQ activity − 0.52 o0.001 − 0.46 o0.001
SGRQ impacts − 0.49 o0.001 − 0.41 o0.001
PRAXIS cohort N= 562
CCQ score − 0.71 o0.001 −0.62 o0.001
Abbreviations: CCQ, clinical COPD questionnaire; SGRQ, Saint Georges
Respiratory Questionnaire.
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used for current symptoms or which of three methods was used
for future risk (number of exacerbations, FEV1%, or either the
FEV1% or number of exacerbations, whichever gives the highest
risk). For example, 42% of patients were categorised into the more
symptoms group when using the MRC dyspnoea scale versus 77%
when using CAT; there were 3.1% in the high-risk group when
using exacerbation frequency compared with 30% when using
FEV1% and 32% when using the highest risk from either FEV1% or
exacerbations. The proportion in the most severe group D varied
from 2.8% using CAT and the exacerbation rate to 46% when
using MRC for symptoms and the highest of exacerbation rate or
FEV1% for future risk.
The GOLD categories were designed to predict future risk for
exacerbations. When examined in relation to the proportion with
an exacerbation in the next 12 months in the OPCRD data set,
different results were found if alternative scoring systems were
used (Figure 2). The use of baseline exacerbation rate rather than
FEV1% showed much better discrimination in detecting future
exacerbations. Using the highest risk or FEV1% on its own made
little difference to the proportion with 1 or more exacerbations in
the next 12 months.
DISCUSSION
Main findings
In this paper, we compared the performance of the DOSE and
ADO indices as measures of current and future disease severity in
various COPD community cohorts. We found that the DOSE index
showed a stronger association than the ADO index with a range of
health status and healthcare consumption outcomes. In assessing
future risk, we found that the hazard ratios for mortality were
higher for ADO index groups than for DOSE index groups.
Conversely, the DOSE index was a better predictor of risk for
future exacerbations and hospital admissions than the ADO index,
Figure 1. The frequency distribution of the GOLD categories according to the methods used to calculate them in the OPC data set.
Table 3. Negative binomial regression of age, smoking status and various measures of baseline COPD severity with the number of hospital
admissions and exacerbations in the 12-month follow-up in the OPC data set
N= 4400 Hospital admissions in the next 12 months Exacerbations in the next 12 months
Incident rate ratio
(95% confidence interval)
AIC Incident rate ratio
(95% confidence interval)
AIC
DOSE index 1.50 (1.33–1.68) 982 1.52 (1.46–1.57) 8,913
ADO index 1.23 (1.10–1.39) 1,013 1.16 (1.12–1.20) 9,352
Number of exacerbations in the
12 months before baseline
1.14 (1.09–1.18) 978 1.28 (1.26–1.31) 8,671
FEV1% 0.976 (0.966–0.986) 1,001 0.987 (0.985–0.990) 9,323
Smoking status: 1,013 9,414
Never 1.00 1.00
Ex 1.17 (0.63–2.16) 1.08 (0.88–1.32)
Current 0.47 (0.23–0.98) 1.00 (0.88–1.32)
MRC dyspnoea scale 1.38 (1.14–1.68) 1,015 1.28 (1.21–1.37) 9,351
Age 1.01 (0.99–1.03) 1,025 1.00 (0.99–1.00) 9,413
Abbreviations: AIC, Akaike’s information criterion; FEV1%, forced expiratory volume in 1 s as a percentage of predicted.
Table 4. Unadjusted hazard ratio (95% confidence interval) for
mortality across DOSE and ADO groups in the PRAXIS cohort
DOSE index
group
Hazard ratio (95%
confidence interval)
ADO index
group
Hazard ratio (95%
confidence interval)
1–3 1.00 0–3 1.00
4–5 4.12 (2.75–6.16) 4–5 4.29 (2.30–8.02)
45 7.05 (4.14–12.0) 45 11.78 (6.62–20.94)
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but previous exacerbations were the best predictor of future
exacerbations in this study as in other studies.15
We found that alternative methods used to calculate the new
GOLD categories resulted in large differences in the distribution of
patient numbers in each category. The categories produced by
different methods cannot be considered equivalent. As measures
of future risk, the GOLD categories calculated using exacerbation
rate had much higher odds ratios (data not shown) than
those produced by FEV1% or the highest risk of FEV1% or
exacerbation rate.
Interpretation of findings in relation to previously published
research
Health status. When assessing the severity of COPD, the impact
of the disease on patients’ lives in terms of current symptoms and
limitations is critical, and is espoused by the GOLD strategy2 and
the National Institute of Clinical Excellence (NICE) guidelines.5 This
study confirms that the DOSE index is superior to, or as good as,
the ADO index in its association with a wide range of patient-
centred outcomes, including health status and quality of life
measured by SGRQ and CCQ. The DOSE index has previously been
shown to be a predictor of decline in health status.14
Mortality. This is not the first study to examine the prognostic
value of multi-component indices. In 144 patients in secondary
care, Oga et al.16 found that the BODE index had a superior
discriminatory value over the DOSE and ADO indices as a predictor
of mortality. Oga et al. also noted that the peak oxygen uptake
(VO2 max) was superior to all three indices as a predictor of
mortality. This finding builds on the original derivation studies of
the BODE index, which highlighted the importance of including
exercise testing in predicting mortality.
The present study confirms previous findings that the ADO
index showed higher hazard ratios for mortality compared with
the DOSE index.16,17 However, the ADO index has a greater
contribution from age than other components; the older the
patient, the higher the ADO index. Thus, a patient with severe
breathlessness and airflow obstruction at the age of 40 years has,
by definition, a lower ADO index than a similar patient aged 90
years. Most clinicians would feel that younger patients with severe
symptoms and airflow obstruction would be of greater concern.18
The new GOLD categories do not perform well in predicting
mortality; in large Spanish primary care data sets the new
categories have no better prognostic value than the old FEV1-
based GOLD stages.19 Thus, for prognostic assessment either the
BODE or the ADO index is preferred.17
Predicting exacerbations and admissions. Patients at increased
risk for exacerbations need to be identified, as it is known that
optimal treatment may reduce the exacerbation rate using drugs,
smoking cessation and pulmonary rehabilitation.15,20 Frequent
exacerbators are at risk of faster decline in their health status, lung
function and death.21–23 Both the DOSE index and the ADO index
were weak predictors of future exacerbations in this study, and a
previous report demonstrated an association with the DOSE index
only.13 This study found the DOSE index to be a better predictor of
future exacerbations than FEV1 or MRC dyspnoea scale, but the
previous exacerbation rate was the best predictor.
The cost of hospital admissions is of major economic
importance, and identifying those at risk would allow pre-
emptive action to reduce that risk.24 A DOSE index of 4 or more
was associated with an almost threefold increased risk for hospital
admission. The DOSE index was a better predictor of admissions
than the ADO and MRC dyspnoea scale, previous exacerbations or
FEV1%. The DOSE index C-statistic compares with other more
recently produced scores such as the SCOPEX, which examined
only patients in clinical trial and risk of exacerbation over six
months and included items such as ‘more COPD maintenance
medications prior to the trial’.25 There are many potential
candidate items for risk prediction models, including co-morbid-
ities, biomarkers and blood oeosinophilia,26–28 but their place in
prediction models is not yet clear.
The GOLD categories. The GOLD strategy (2011, updated 2015)
advocated using a new assessment system of categories A–D
based on current symptoms and future risk.2 The calculation of the
four GOLD categories is complex and may not be practicable in
primary care. The distribution within large primary care data sets
has been demonstrated, but only using a limited range of possible
methods of calculation.29 Our study is the first to examine all
possible ways to calculate the GOLD categories. As in previous
studies we found that the distribution into GOLD categories is
uneven and varies greatly according to the method used to
calculate them.8,19 It shows that the predictive value of future risk
varies greatly according to the methods used to derive the
categories. The treatment guidance based on future risk includes
recommending inhaled steroids if they are ‘higher risk’; we found
a 10-fold variation in the proportion of patients recommended
inhaled steroids: only 3.1% in the high-risk group when using
Figure 2. The percentage of patients with one or more exacerbations in the follow-up period as seen in the GOLD categories calculated by
alternative methods.
Multi-component assessment of COPD
RC Jones et al
4
npj Primary Care Respiratory Medicine (2016) 16010 © 2016 Primary Care Respiratory Society UK/Macmillan Publishers Limited
exacerbation frequency, compared with 30% when using FEV1%
and 32% when using the highest risk from either FEV1% or
exacerbations. If GOLD categories are to be used in practice,
then their method of calculation must be stated, such as the
subcategories C1, C2 and C3 and D1, D2 and D3.8 Unfortunately
using subcategories adds to the complexity of using the system in
clinical practice.
We have shown that, in considering the incident rate ratios of
future exacerbations, the prior exacerbation rate had a stronger
association than the FEV1%. The use of FEV1% in calculating future
risk is thus not supported by evidence. If the GOLD categories are
reviewed, we recommend that consideration be made to
removing FEV1% as a measure of future risk and to use only
exacerbation frequency.
Strengths and limitations of this study
Our data sets come from routinely collected data and are subject
to missing items. Therefore, a number of patients’ data could not
be included in the current analyses. In the OPCRD data set, as
some people had data for less than the specified 12 months,
seasonal bias may have influenced exacerbation rates. In primary
care, routinely collected data on spirometry are of variable
quality.30 Although this means that there may be less accurate
diagnoses than in efficacy studies, the data sets reflect people
with a clinical diagnosis in real life and only those patients whose
FEV1/FVC ratio was o0.7 were included in the current analyses.
Some data sets comprised a small number of patients, resulting
in limited statistical power to detect associations. Thus, caution
needs to be employed in generalising these findings.
Implications for future research, policy and practice
When assessing patients in clinical practice, whether for quality
improvement audits or for reporting patient status in primary and
secondary care, we would concur with the NICE guidelines that
the BODE index is the index of choice when 6MWT data are
available.5 When the 6MWT is not available, the DOSE index is
preferable to the ADO index for assessing current symptoms and
future risk of exacerbations and hospitalisations. The risk of
mortality is better predicted by the ADO or BODE indices than by
the GOLD categories and the DOSE index.17 Given that the GOLD
categories when calculated by the alternative methods produced
greatly varying populations and variable value in predicting risk,
they cannot be recommended for routine care or treatment
decisions. They could be very valuable if simplified to use only
exacerbations to define risk and CAT or CCQ to define symptoms.
Conclusions
Multidimensional systems for assessing COPD severity were
assessed in real-life data from several community settings and
none were found to be excellent. We found the DOSE index to be
more closely associated than the ADO index with health status,
exercise capacity, current exacerbations and hospital admissions.
The DOSE index was a stronger predictor of hospital admissions
and exacerbations in the subsequent year than the airflow
obstruction or the MRC dyspnoea scale. The ADO index showed
higher hazard ratios for mortality compared with the DOSE index.
The GOLD categories allow alternative methods to calculate them,
but the different methods produce very different groups and
perform inconsistently as measures of future risk. Use of
exacerbation frequency in the calculation of the GOLD categories
produced better discrimination than FEV1%, and this approach
could be extremely helpful in clinical care. If the BODE index data
are not available, the ADO index is a better predictor of mortality
than DOSE, but the DOSE index is better correlated with measures
of current symptoms and future risk for exacerbations and
hospitalisations.
MATERIALS AND METHODS
In a historical observational study using three existing databases of
routinely collected clinical data, we performed an assessment of the GOLD
categories and ADO and DOSE indices as measures of current symptoms
and future risk. The component items of the indices and GOLD categories
are shown in Table 1.
We investigated the associations of both the DOSE and ADO indices
with current symptoms, exacerbations and hospital admissions, as well as
with future events of exacerbations, admissions and mortality. As the
GOLD categories are nominal variables, not linear scales, it was not
possible to directly compare them with the DOSE and ADO indices. We
examined whether the GOLD categories were equivalent when produced
using the various alternative methods available and to evaluate how well
they reflected current symptoms and future risks in large data sets of
COPD patients in community settings encompassing the full range of
COPD severity.
Data sets
The UNLOCK Group of the International Primary Care Respiratory Group31
and the Respiratory Effectiveness Group (www.effectivenessevaluation.org)
provided a range of suitable data sets. From these we included people
with a clinical diagnosis whose FEV1/FVC ratio was o0.7. The data sources
used were:
1. UK primary care data from the OPCRD database (http://www.
optimumpatientcare.org/Html_Docs/OPCRD.html). Data were routinely
collected from 131 primary care practices on COPD patients in primary
care. When the GOLD categories in the OPCRD data set were examined,
we found 7,105 COPD patients aged 40 years and over who had valid
MRC, exacerbation and FEV1% predicted values, as well as outcome
variables including hospital admissions for exacerbations of COPD
and future exacerbations. There were 4,400 patients with complete
follow-up data, 3,015 of whom had valid CAT and MRC scores and a
valid FEV1%.
2. Data from a pulmonary community rehabilitation clinical trial in
Bocholtz, Holland, provided 152 primary care COPD patients over a
two-year period, including data from the Saint Georges Respiratory
Questionnaire (SGRQ) and the Clinical COPD Questionnaire (CCQ). The
study provided 152 patients at baseline,32 133 at 12 months and 91
patients at 24 months; some variables were not recorded in all patients
and valid numbers are as stated in the text.
3. Data from the PRAXIS study in Sweden consisted of 562 randomly
selected patients, 34–75 years old, with a diagnosis of COPD from
primary care (57%) and secondary care (43%) with complete DOSE
and ADO indices. Data were collected in 2005 by self-completion
questionnaire and record review during 2000–2003. Mortality data from
2005 to 2010 were provided from the Swedish Board of Health and
Welfare.12
Primary care systems in different countries vary, but in Holland, UK and
Sweden there is similar availability of drugs, guidelines and similar referral
systems to secondary care and pulmonary rehabilitation (albeit without
universal access). The baseline characteristics of the three cohorts are
shown in the online supplement.
Statistical methods
Spearman’s rank correlation was used to assess the association between
each of the DOSE and ADO indices and the health status measures and
markers of healthcare consumption in each of the three data sets. In the
OPCRD data set, logistic regression analysis was used to calculate the
unadjusted odds ratio (95% CI) for one or more hospital admissions and for
one or more exacerbations in the subsequent year for a unit increase in the
DOSE or ADO index. Receiver operator characteristic analyses and areas
under the curve (which is the equivalent of the c-statistic in a logistic
model) were produced for DOSE and ADO indices in relation to the
prediction of future risk for exacerbations and admissions for the OPCRD
data. Negative binomial regression models were used to give unadjusted
incident rate ratios (95% CI) of number of exacerbations and hospitalisa-
tions during follow-up for each of DOSE and ADO indices and a range of
health status measures in the OPCRD data set. The Akaike’s information
criterion (AIC) of each model was compared; the model with the lowest AIC
was deemed the ‘best’ fit. All statistical models were based on a complete
case analysis.
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Using the PRAXIS study data, Cox regression was used to calculate the
hazard ratio (95% CI) of mortality during follow-up for different DOSE and
ADO index groups before and after adjustment for gender and pre-existing
cardiovascular disease.
Using the OPCRD data set, descriptive methods were used to compare
features of the GOLD categories when derived using the recommended
alternative methods. Logistic regression was used to examine whether the
GOLD patient group was an independent predictor of future admissions or
exacerbations. Finally, the Kruskall–Wallis test was used to examine the
distribution of DOSE and ADO indices across GOLD patient groups.
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